# Vinorelbine for Recurrent ALCL-2017

> **NCT03443128** · PHASE2 · COMPLETED · sponsor: **Children's Cancer Group, China** · enrollment: 20 (estimated)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Vinorelbine

## Interventions

- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03443128
- **Lead sponsor:** Children's Cancer Group, China
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2024-12
- **Final completion:** 2025-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443128, "Vinorelbine for Recurrent ALCL-2017". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03443128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*